AOD-9604 Research Guide

Full name: Advanced Obesity Drug Fragment 176-191 (Modified)

A modified fragment of human growth hormone (amino acids 176-191) that stimulates lipolysis and inhibits lipogenesis. Originally developed as an anti-obesity drug with no effect on IGF-1 or blood glucose.

How AOD-9604 Works

Mimics the lipolytic domain of growth hormone (hGH 176-191), stimulating fat oxidation and inhibiting de novo lipogenesis through pathways independent of IGF-1 and growth signaling.

Dosing Protocol

• Typical dose: 300 mcg
• Frequency: Daily (morning, fasted)
• Duration: 12 weeks
• Route: Subcutaneous injection

Reported Benefits

• Fat loss without muscle wasting
• No effect on blood sugar
• Cartilage repair properties
• No HGH-related side effects

Potential Side Effects

• Injection site soreness
• Headache
• Mild stomach discomfort

Research Citations

1. AOD-9604 lipolytic effects in obese subjects (2019) - Demonstrated significant fat mass reduction without changes in IGF-1 or glucose tolerance.
2. HGH fragment 176-191 cartilage regeneration (2020) - Showed chondroprotective effects and stimulated proteoglycan synthesis in osteoarthritic cartilage.

Related Weight Management Compounds

• Semaglutide - Full Profile
• Tirzepatide - Full Profile
• Retatrutide - Full Profile
• Tesofensine - Full Profile
• CagriSema - Full Profile
• Survodutide - Full Profile

View full AOD-9604 profile with 3D molecule viewer →